NovoCure Limited(NASDAQ:NVCR) 
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients wit...
Website: https://www.novocure.com/
Founded: 2000
Full Time Employees: 782
CEO: Asaf Danziger
Sector: Healthcare
Industry: Medical Instruments & Supplies
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
net revenues | 174,055,000 | 174,350,000 | 167,204,000 | 158,805,000 | 154,994,000 | 161,266,000 | 155,095,000 | 150,356,000 | 138,503,000 | 133,784,000 | 127,321,000 | 126,051,000 | 122,182,000 | 128,429,000 | 130,998,000 | 140,866,000 | 137,547,000 | 133,213,000 | 133,606,000 | 133,517,000 | 134,695,000 | 143,953,000 | 132,660,000 | 115,925,000 | 101,828,000 | 99,234,000 | 92,062,000 | 86,713,000 | 73,309,000 | 69,674,000 | 64,756,000 | 61,514,000 | 52,125,000 | 53,661,000 | 50,109,000 | 38,376,000 | 34,880,000 | 30,242,000 | 21,674,000 | 17,919,000 | 13,053,000 | 12,383,000 | 8,953,000 |
cost of revenues | 38,929,000 | 42,157,000 | 44,729,000 | 41,472,000 | 38,521,000 | 33,466,000 | 35,372,000 | 34,654,000 | 33,689,000 | 32,556,000 | 32,092,000 | 34,018,000 | 29,614,000 | 28,888,000 | 29,749,000 | 28,503,000 | 27,727,000 | 29,687,000 | 30,206,000 | 28,599,000 | 26,385,000 | 28,136,000 | 28,395,000 | 25,474,000 | 24,496,000 | 24,786,000 | 22,900,000 | 21,106,000 | 19,814,000 | 23,028,000 | 18,949,000 | 19,833,000 | 18,238,000 | 15,640,000 | 15,153,000 | 13,152,000 | 11,664,000 | 10,973,000 | 11,118,000 | 9,797,000 | 7,982,000 | 6,304,000 | 5,659,000 |
gross profit | 135,126,000 | 132,193,000 | 122,475,000 | 117,333,000 | 116,473,000 | 127,800,000 | 119,723,000 | 115,702,000 | 104,814,000 | 101,228,000 | 95,229,000 | 92,033,000 | 92,568,000 | 99,541,000 | 101,249,000 | 112,363,000 | 109,820,000 | 103,526,000 | 103,400,000 | 104,918,000 | 108,310,000 | 115,817,000 | 104,265,000 | 90,451,000 | 77,332,000 | 74,448,000 | 69,162,000 | 65,607,000 | 53,495,000 | 46,646,000 | 45,807,000 | 41,681,000 | 33,887,000 | 38,021,000 | 34,956,000 | 25,224,000 | 23,216,000 | 19,269,000 | 10,556,000 | 1,710,000 | 5,071,000 | 6,079,000 | 3,294,000 |
yoy | 16.01% | 3.44% | 2.30% | 1.41% | 11.12% | 26.25% | 25.72% | 25.72% | 13.23% | 1.69% | -5.95% | -18.09% | -15.71% | -3.85% | -2.08% | 7.10% | 1.39% | -10.61% | -0.83% | 15.99% | 40.06% | 55.57% | 50.75% | 37.87% | 44.56% | 59.60% | 50.99% | 57.40% | 57.86% | 22.68% | 31.04% | 65.24% | 45.96% | 97.32% | 231.15% | 1375.09% | 357.82% | 216.98% | 220.46% | ||||
qoq | 2.22% | 7.93% | 4.38% | 0.74% | -8.86% | 6.75% | 3.48% | 10.39% | 3.54% | 6.30% | 3.47% | -0.58% | -7.01% | -1.69% | -9.89% | 2.32% | 6.08% | 0.12% | -1.45% | -3.13% | -6.48% | 11.08% | 15.27% | 16.96% | 3.87% | 7.64% | 5.42% | 22.64% | 14.68% | 1.83% | 9.90% | 23.00% | -10.87% | 8.77% | 38.58% | 8.65% | 20.48% | 82.54% | 517.31% | -66.28% | -16.58% | 84.55% | |
operating costs and expenses: | |||||||||||||||||||||||||||||||||||||||||||
research, development and clinical studies | 58,336,000 | 60,905,000 | 54,029,000 | 55,833,000 | 53,777,000 | 51,210,000 | 51,882,000 | 54,955,000 | 51,598,000 | 54,308,000 | 53,623,000 | 55,427,000 | 59,704,000 | 54,820,000 | 51,956,000 | 57,075,000 | 42,234,000 | ||||||||||||||||||||||||||
sales and marketing | 58,357,000 | 68,660,000 | 58,546,000 | 57,066,000 | 55,792,000 | 67,411,000 | 59,830,000 | 56,616,000 | 55,206,000 | 59,188,000 | 57,964,000 | 58,488,000 | 51,169,000 | 49,629,000 | 41,395,000 | 44,750,000 | 37,884,000 | 38,982,000 | 32,580,000 | 34,138,000 | 31,357,000 | 31,359,000 | 29,364,000 | 28,461,000 | 28,834,000 | 26,804,000 | 23,830,000 | 23,708,000 | 22,333,000 | 21,208,000 | 19,124,000 | 19,196,000 | 18,135,000 | 16,025,000 | 16,387,000 | 16,360,000 | 14,756,000 | 15,678,000 | 15,865,000 | 14,598,000 | 13,308,000 | 14,724,000 | 8,916,000 |
general and administrative | 85,853,000 | 43,021,000 | 45,921,000 | 43,955,000 | 44,769,000 | 72,483,000 | 40,103,000 | 37,711,000 | 39,530,000 | 39,448,000 | 41,887,000 | 40,778,000 | 41,944,000 | 38,070,000 | 32,509,000 | 31,666,000 | 30,508,000 | 31,011,000 | 31,231,000 | 32,760,000 | 31,125,000 | 28,364,000 | 27,061,000 | 25,404,000 | 26,608,000 | 23,750,000 | 22,711,000 | 21,249,000 | 20,238,000 | 19,068,000 | 18,855,000 | 18,208,000 | 17,325,000 | 16,454,000 | 15,215,000 | 15,023,000 | 12,422,000 | 12,997,000 | 12,723,000 | 13,031,000 | 12,256,000 | 11,116,000 | 8,405,000 |
total operating costs and expenses | 202,546,000 | 172,586,000 | 158,496,000 | 156,854,000 | 154,338,000 | 191,104,000 | 151,815,000 | 149,282,000 | 146,334,000 | 152,944,000 | 153,474,000 | 154,693,000 | 152,817,000 | 142,519,000 | 125,860,000 | 133,491,000 | 110,626,000 | 126,924,000 | 111,952,000 | 117,213,000 | 108,398,000 | 103,725,000 | 89,243,000 | 83,783,000 | 80,713,000 | 74,295,000 | 65,307,000 | 64,411,000 | 59,613,000 | 55,310,000 | 51,053,000 | 48,766,000 | 46,564,000 | 42,527,000 | 40,875,000 | 40,754,000 | 36,589,000 | 37,146,000 | 38,821,000 | 38,947,000 | 37,009,000 | 36,685,000 | 27,532,000 |
operating income | -67,420,000 | -40,393,000 | -36,021,000 | -39,521,000 | -37,865,000 | -63,304,000 | -32,092,000 | -33,580,000 | -41,520,000 | -51,716,000 | -58,245,000 | -62,660,000 | -60,249,000 | -42,978,000 | -24,611,000 | -21,128,000 | -806,000 | -23,398,000 | -8,552,000 | -12,295,000 | -88,000 | 12,092,000 | 15,022,000 | 6,668,000 | -3,381,000 | 153,000 | 3,855,000 | 1,196,000 | -6,118,000 | -8,664,000 | -5,246,000 | -7,085,000 | -12,677,000 | -4,506,000 | -5,919,000 | -15,530,000 | -13,373,000 | -17,877,000 | -28,265,000 | -37,237,000 | -31,938,000 | -30,606,000 | -24,238,000 |
yoy | 78.05% | -36.19% | 12.24% | 17.69% | -8.80% | 22.41% | -44.90% | -46.41% | -31.09% | 20.33% | 136.66% | 196.57% | 7375.06% | 83.68% | 187.78% | 71.84% | 815.91% | -293.50% | -156.93% | -284.39% | -97.40% | 7803.27% | 289.68% | 457.53% | -44.74% | -101.77% | -173.48% | -116.88% | -51.74% | 92.28% | -11.37% | -54.38% | -5.20% | -74.79% | -79.06% | -58.29% | -58.13% | -41.59% | 16.61% | ||||
qoq | 66.91% | 12.14% | -8.86% | 4.37% | -40.19% | 97.26% | -4.43% | -19.12% | -19.72% | -11.21% | -7.05% | 4.00% | 40.19% | 74.63% | 16.49% | 2521.34% | -96.56% | 173.60% | -30.44% | 13871.59% | -100.73% | -19.50% | 125.28% | -297.22% | -2309.80% | -96.03% | 222.32% | -119.55% | -29.39% | 65.15% | -25.96% | -44.11% | 181.34% | -23.87% | -61.89% | 16.13% | -25.19% | -36.75% | -24.09% | 16.59% | 4.35% | 26.27% | |
financial income (expenses) | -1,838,000 | 4,527,750 | 5,999,000 | 4,542,000 | 7,570,000 | 7,809,000 | 10,507,000 | 10,851,000 | 9,878,000 | 6,987,000 | 10,023,000 | 8,756,000 | 9,169,000 | ||||||||||||||||||||||||||||||
income before income tax | -69,258,000 | -23,824,000 | -30,022,000 | -34,979,000 | -30,295,000 | -18,989,000 | -21,585,000 | -22,729,000 | -31,642,000 | -38,301,500 | -48,222,000 | -53,904,000 | -51,080,000 | -12,322,000 | -23,417,000 | -23,356,000 | -2,515,000 | -6,625,500 | -10,533,000 | -13,235,000 | -2,734,000 | 2,319,250 | 11,039,000 | 4,051,000 | -5,813,000 | ||||||||||||||||||
income tax | 1,880,000 | -16,455,000 | 7,248,000 | 5,160,000 | 4,024,000 | 10,716,000 | 8,985,000 | 10,646,000 | 7,118,000 | 8,545,000 | 1,263,000 | 3,514,000 | 1,981,000 | 4,745,000 | 3,159,000 | 652,000 | 2,132,000 | 885,000 | 2,591,000 | 1,406,000 | 1,394,000 | 3,908,000 | 1,755,000 | 2,396,000 | -9,765,000 | ||||||||||||||||||
net income | -71,138,000 | -24,499,000 | -37,270,000 | -40,139,000 | -34,319,000 | -65,922,000 | -30,570,000 | -33,375,000 | -38,760,000 | -47,079,000 | -49,485,000 | -57,418,000 | -53,061,000 | -37,303,000 | -26,576,000 | -24,008,000 | -4,647,000 | -26,458,000 | -13,124,000 | -14,641,000 | -4,128,000 | 4,917,000 | 9,284,000 | 1,655,000 | 3,952,000 | 4,260,000 | 1,930,000 | -1,270,000 | -12,150,000 | -15,631,000 | -11,694,000 | -15,510,000 | -20,724,000 | -10,945,000 | -11,498,000 | -21,174,000 | -18,045,000 | -22,168,000 | -33,628,000 | -40,612,000 | -35,437,000 | -32,928,000 | -26,023,000 |
yoy | 107.28% | -62.84% | 21.92% | 20.27% | -11.46% | 40.02% | -38.22% | -41.87% | -26.95% | 26.21% | 86.20% | 139.16% | 1041.83% | 40.99% | 102.50% | 63.98% | 12.57% | -638.09% | -241.36% | -984.65% | -204.45% | 15.42% | 381.04% | -230.31% | -132.53% | -127.25% | -116.50% | -91.81% | -41.37% | 42.81% | 1.70% | -26.75% | 14.85% | -50.63% | -65.81% | -47.86% | -49.08% | -32.68% | 29.22% | ||||
qoq | 190.37% | -34.27% | -7.15% | 16.96% | -47.94% | 115.64% | -8.40% | -13.89% | -17.67% | -4.86% | -13.82% | 8.21% | 42.24% | 40.36% | 10.70% | 416.63% | -82.44% | 101.60% | -10.36% | 254.68% | -183.95% | -47.04% | 460.97% | -58.12% | -7.23% | 120.73% | -251.97% | -89.55% | -22.27% | 33.67% | -24.60% | -25.16% | 89.35% | -4.81% | -45.70% | 17.34% | -18.60% | -34.08% | -17.20% | 14.60% | 7.62% | 26.53% | |
basic and diluted net income per ordinary share | -620 | -220 | -330 | -360 | -310 | -610 | -280 | -310 | -360 | -440 | -460 | -540 | -10 | -130 | -170 | -130 | |||||||||||||||||||||||||||
weighted-average number of ordinary shares used in computing basic and diluted net income per share | 114,149,838 | 111,471,991 | 111,908,252 | 111,572,191 | 110,281,832 | 107,834,368 | 108,247,716 | 107,700,284 | 107,266,198 | 106,391,178 | 106,772,814 | 106,289,073 | 97,237,549 | 96,356,317 | 94,811,282 | 91,828,043 | 92,911,375 | ||||||||||||||||||||||||||
basic net income per ordinary share | -500 | -350 | -250 | -230 | -40 | -250 | -130 | -140 | -40 | 50 | 90 | 20 | 40 | -30 | 20 | ||||||||||||||||||||||||||||
weighted-average number of ordinary shares used in computing basic net income per share | 105,667,072 | 104,660,476 | 104,884,583 | 104,627,789 | 104,186,120 | 103,433,274 | 103,731,147 | 103,484,866 | 102,633,545 | 100,930,866 | 101,234,306 | 100,718,893 | 99,877,567 | 98,485,519 | |||||||||||||||||||||||||||||
diluted net income per ordinary share | -0.5 | -0.35 | -0.25 | -0.23 | -0.04 | -0.25 | -0.13 | -0.14 | -0.04 | 0.04 | 0.09 | 0.02 | 0.04 | -0.03 | 0.02 | ||||||||||||||||||||||||||||
weighted-average number of ordinary shares used in computing diluted net income per share | 105,667,072 | 104,660,476 | 104,884,583 | 104,627,789 | 104,186,120 | 103,433,274 | 103,731,147 | 103,484,866 | 102,633,545 | 108,877,648 | 108,643,814 | 107,647,802 | 108,100,623 | 107,604,578 | |||||||||||||||||||||||||||||
financial expenses (income) | 685,750 | -1,194,000 | 2,228,000 | 1,709,000 | 2,175,000 | 1,981,000 | 940,000 | 2,646,000 | 3,267,000 | 3,983,000 | 2,617,000 | 2,432,000 | 1,745,000 | 2,555,000 | 1,239,000 | 2,371,000 | 2,527,500 | 2,397,000 | |||||||||||||||||||||||||
research, development and clinical trials | 36,093,000 | 48,141,000 | 50,315,000 | 45,916,000 | 44,002,000 | 32,818,000 | 29,918,000 | 25,271,000 | 23,741,000 | 18,766,000 | 19,454,000 | 17,042,000 | 15,034,000 | 13,074,000 | 11,362,000 | 11,104,000 | 10,048,000 | 9,273,000 | 9,371,000 | 9,411,000 | 8,471,000 | 10,233,000 | 11,318,000 | 11,445,000 | 10,845,000 | 10,211,000 | |||||||||||||||||
income before income taxes | -1,592,000 | 1,300,000 | -43,000 | -8,489,000 | -10,824,000 | -7,643,000 | -9,945,000 | -17,530,000 | |||||||||||||||||||||||||||||||||||
income taxes | 1,064,500 | -630,000 | 1,227,000 | 3,661,000 | 4,807,000 | 4,051,000 | 5,565,000 | 3,194,000 | |||||||||||||||||||||||||||||||||||
financial expenses | 2,860,000 | 4,853,000 | -15,954,000 | 2,156,000 | -2,183,000 | -2,446,000 | -9,440,000 | 2,189,000 | 555,000 | 549,000 | -874,000 | -809,000 | |||||||||||||||||||||||||||||||
basic and diluted net loss per ordinary share | -170 | -230 | -130 | -130 | -240 | -210 | -250 | -390 | -480 | -420 | 2,540 | -2,090 | |||||||||||||||||||||||||||||||
weighted-average number of ordinary shares used in computing basic and diluted net loss per share | 91,331,862 | 89,985,612 | 88,546,719 | 89,125,646 | 88,218,868 | 87,452,983 | 85,558,448 | 85,774,874 | 85,274,683 | 84,397,164 | 30,401,603 | 12,431,586 | |||||||||||||||||||||||||||||||
impairment of field equipment | 6,412,000 | ||||||||||||||||||||||||||||||||||||||||||
loss before income tax expense | -10,401,750 | -8,075,000 | -17,713,000 | -15,819,000 | -25,183,250 | -30,454,000 | -37,792,000 | -32,487,000 | -18,916,750 | -25,047,000 | |||||||||||||||||||||||||||||||||
income tax expense | 2,277,500 | 3,423,000 | 3,461,000 | 2,226,000 | 2,236,000 | 3,174,000 | 2,820,000 | 2,950,000 | 746,500 | 976,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 87,527,000 | 93,548,000 | 342,119,000 | 149,624,000 | 127,279,000 | 163,767,000 | 185,422,000 | 164,796,000 | 240,821,000 | 154,860,000 | 156,978,000 | 185,963,000 | 115,326,000 | 243,805,000 | 367,014,000 | 190,739,000 | 208,802,000 | 689,837,000 | 349,124,000 | 314,547,000 | 234,674,000 | 234,461,000 | 196,784,000 | 181,919,000 | 177,321,000 | 208,034,000 | 180,073,000 | 152,067,000 | 140,622,000 | 122,959,000 | 114,456,000 | 111,603,000 | 78,592,000 | 82,104,000 | 80,190,000 | 84,587,000 | 99,780,000 | 115,822,000 | 80,871,000 | 115,932,000 | 119,423,000 | 110,324,000 |
short-term investments | 344,477,000 | 354,126,000 | 691,382,000 | 761,901,000 | 801,852,000 | 796,106,000 | 774,476,000 | 786,390,000 | 669,795,000 | 766,388,000 | 783,837,000 | 772,072,000 | 854,099,000 | 726,515,000 | 581,503,000 | 741,562,000 | 728,898,000 | 243,948,000 | 549,907,000 | 549,855,000 | 607,902,000 | 149,930,000 | 149,349,000 | 148,769,000 | 104,565,000 | 104,511,000 | 104,535,000 | 105,256,000 | 104,743,000 | 104,499,000 | 104,712,000 | 104,719,000 | 104,453,000 | 104,186,000 | 104,664,000 | 119,854,000 | 119,724,000 | 119,979,000 | 119,842,000 | 150,001,000 | 26,999,000 | |
restricted cash | 9,797,000 | 9,842,000 | 2,519,000 | 2,509,000 | 2,152,000 | 2,327,000 | 3,777,000 | 3,647,000 | 1,743,000 | 1,652,000 | 516,000 | 676,000 | 508,000 | 231,000 | 749,000 | 889,000 | 807,000 | 855,000 | 11,463,000 | 11,430,000 | 11,499,000 | 920,000 | 801,000 | 786,000 | 2,095,000 | 2,134,000 | 2,110,000 | 2,094,000 | 2,134,000 | 2,199,000 | 2,169,000 | 2,158,000 | 2,126,000 | 2,129,000 | 1,537,000 | 1,536,000 | 267,000 | 72,000 | 99,000 | 86,000 | 87,000 | 166,000 |
trade receivables | 93,274,000 | 89,435,000 | 85,230,000 | 89,915,000 | 84,507,000 | 74,226,000 | 67,060,000 | 64,703,000 | 61,221,000 | 65,133,000 | 70,988,000 | 74,830,000 | 86,261,000 | 87,552,000 | 97,563,000 | 100,965,000 | 93,567,000 | 94,129,000 | 90,436,000 | 92,514,000 | 96,699,000 | 84,561,000 | 76,026,000 | 65,139,000 | 58,859,000 | 49,904,000 | 42,533,000 | 39,220,000 | 36,523,000 | 35,388,000 | 37,643,000 | 34,044,000 | 29,567,000 | 23,000,000 | 13,888,000 | 11,825,000 | 6,339,000 | |||||
receivables and prepaid expenses | 53,130,000 | 58,669,000 | 39,500,000 | 39,139,000 | 34,043,000 | 35,063,000 | 25,437,000 | 32,858,000 | 22,677,000 | 23,163,000 | 20,148,000 | 23,730,000 | 25,959,000 | 17,478,000 | 18,195,000 | 17,343,000 | 17,025,000 | 17,595,000 | 17,946,000 | 18,922,000 | 21,245,000 | 37,064,000 | 38,104,000 | 42,483,000 | 29,202,000 | 17,917,000 | 15,302,000 | 13,619,000 | 14,279,000 | 9,895,000 | 11,216,000 | 9,939,000 | 8,105,000 | 5,559,000 | 11,544,000 | 14,899,000 | 10,084,000 | 11,840,000 | 12,534,000 | 11,335,000 | 10,799,000 | 10,164,000 |
inventories | 43,458,000 | 41,111,000 | 39,104,000 | 40,211,000 | 39,468,000 | 35,086,000 | 39,096,000 | 40,442,000 | 38,152,000 | 36,806,000 | 33,023,000 | 31,723,000 | 29,376,000 | 26,792,000 | 29,531,000 | 29,084,000 | 24,427,000 | 22,642,000 | 26,690,000 | 27,968,000 | 27,422,000 | 26,479,000 | 26,136,000 | 22,502,000 | 23,701,000 | 24,388,000 | 25,454,000 | 24,138,000 | 22,555,000 | 21,641,000 | 19,906,000 | 20,386,000 | 22,025,000 | 24,642,000 | 25,147,000 | 25,949,000 | 25,549,000 | 23,972,000 | 21,215,000 | 16,446,000 | 13,594,000 | 11,149,000 |
total current assets | 631,663,000 | 646,731,000 | 1,199,854,000 | 1,083,299,000 | 1,089,301,000 | 1,106,575,000 | 1,095,268,000 | 1,092,836,000 | 1,034,409,000 | 1,048,002,000 | 1,065,490,000 | 1,088,994,000 | 1,111,529,000 | 1,102,373,000 | 1,094,555,000 | 1,080,582,000 | 1,073,526,000 | 1,069,006,000 | 1,045,566,000 | 1,015,236,000 | 999,441,000 | 383,485,000 | 487,781,000 | 462,178,000 | 439,947,000 | 406,942,000 | 369,983,000 | 335,673,000 | 321,369,000 | 296,825,000 | 289,889,000 | 282,842,000 | 245,134,000 | 241,887,000 | 236,492,000 | 243,460,000 | 261,873,000 | 271,430,000 | 234,698,000 | 263,641,000 | 293,904,000 | 158,802,000 |
long-term assets: | ||||||||||||||||||||||||||||||||||||||||||
property and equipment | 76,279,000 | 77,606,000 | 79,976,000 | 80,333,000 | 79,599,000 | 77,660,000 | 73,251,000 | 66,477,000 | 51,479,000 | 45,564,000 | 41,156,000 | 36,454,000 | 32,678,000 | 29,745,000 | 26,561,000 | 25,072,000 | 22,693,000 | 11,699,000 | 11,857,000 | 11,733,000 | 11,395,000 | 10,271,000 | 10,530,000 | 9,778,000 | 9,342,000 | 8,425,000 | 8,399,000 | 8,421,000 | 8,442,000 | 8,564,000 | 8,891,000 | 8,902,000 | 9,031,000 | 9,361,000 | 9,621,000 | 10,039,000 | 9,812,000 | 9,886,000 | 8,813,000 | 7,090,000 | 6,552,000 | 6,106,000 |
field equipment | 23,309,000 | 22,066,000 | 20,549,000 | 18,591,000 | 16,914,000 | 14,811,000 | 12,913,000 | 11,719,000 | 11,384,000 | 11,357,000 | 11,519,000 | 12,216,000 | 12,684,000 | 11,985,000 | 12,377,000 | 12,792,000 | 12,923,000 | 12,553,000 | 12,042,000 | 12,132,000 | 11,230,000 | 9,132,000 | 8,339,000 | 8,467,000 | 7,684,000 | 8,139,000 | 7,466,000 | 7,266,000 | 6,924,000 | 7,300,000 | 8,108,000 | 9,020,000 | 9,036,000 | 8,948,000 | 9,061,000 | 9,278,000 | 8,808,000 | 8,042,000 | 5,850,000 | 7,211,000 | 6,029,000 | 4,516,000 |
right-of-use assets | 45,475,000 | 47,327,000 | 48,402,000 | 48,089,000 | 48,511,000 | 27,120,000 | 28,330,000 | 29,076,000 | 34,835,000 | 29,014,000 | 26,278,000 | 25,529,000 | 23,596,000 | 19,405,000 | 18,281,000 | 19,937,000 | 18,267,000 | 16,460,000 | 16,964,000 | 17,741,000 | 19,009,000 | 17,122,000 | 17,429,000 | 17,201,000 | 17,571,000 | 14,635,000 | 14,659,000 | 13,920,000 | ||||||||||||||
other long-term assets | 11,200,000 | 10,596,000 | 12,413,000 | 15,563,000 | 14,484,000 | 14,618,000 | 12,224,000 | 12,062,000 | 14,022,000 | 12,416,000 | 14,572,000 | 11,147,000 | 11,161,000 | 10,707,000 | 10,898,000 | 11,827,000 | 12,086,000 | 10,735,000 | 10,630,000 | 10,788,000 | 10,908,000 | 11,039,000 | 4,860,000 | 4,824,000 | 4,904,000 | 5,717,000 | 5,682,000 | 4,975,000 | 2,945,000 | 2,709,000 | 2,877,000 | 2,602,000 | 1,986,000 | 1,978,000 | 1,766,000 | 1,756,000 | 1,500,000 | 1,646,000 | 1,076,000 | 992,000 | 772,000 | 1,705,000 |
total long-term assets | 156,263,000 | 157,595,000 | 161,340,000 | 162,576,000 | 159,508,000 | 134,209,000 | 126,718,000 | 119,334,000 | 111,720,000 | 98,351,000 | 93,525,000 | 85,346,000 | 80,119,000 | 71,842,000 | 68,117,000 | 69,628,000 | 65,969,000 | 51,447,000 | 51,493,000 | 52,394,000 | 52,542,000 | 47,564,000 | 41,158,000 | 40,270,000 | 39,501,000 | 36,916,000 | 36,206,000 | 34,582,000 | 18,424,000 | 18,687,000 | 19,987,000 | 20,637,000 | 20,164,000 | 20,391,000 | 20,550,000 | 21,168,000 | 20,208,000 | 19,663,000 | 15,821,000 | 15,377,000 | 13,432,000 | 14,979,000 |
total assets | 787,926,000 | 804,326,000 | 1,361,194,000 | 1,245,875,000 | 1,248,809,000 | 1,240,784,000 | 1,221,986,000 | 1,212,170,000 | 1,146,129,000 | 1,146,353,000 | 1,159,015,000 | 1,174,340,000 | 1,191,648,000 | 1,174,215,000 | 1,162,672,000 | 1,150,210,000 | 1,139,495,000 | 1,120,453,000 | 1,097,059,000 | 1,067,630,000 | 1,051,983,000 | 431,049,000 | 528,939,000 | 502,448,000 | 479,448,000 | 443,858,000 | 406,189,000 | 370,255,000 | 339,793,000 | 315,512,000 | 309,876,000 | 303,479,000 | 265,298,000 | 262,278,000 | 257,042,000 | 264,628,000 | 282,081,000 | 291,093,000 | 250,519,000 | 279,018,000 | 307,336,000 | 173,781,000 |
the accompanying notes are an integral part of these unaudited consolidated financial statements. | ||||||||||||||||||||||||||||||||||||||||||
novocure limited and subsidiaries consolidated balance sheets | ||||||||||||||||||||||||||||||||||||||||||
u.s. dollars in thousands | ||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders' equity | ||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||
trade payables | 127,239,000 | 122,231,000 | 118,922,000 | 103,678,000 | 95,086,000 | 105,086,000 | 91,319,000 | 90,171,000 | 94,391,000 | 79,668,000 | 82,536,000 | 81,469,000 | 85,197,000 | 77,026,000 | 79,910,000 | 69,186,000 | 72,600,000 | 60,005,000 | 56,785,000 | 52,703,000 | 53,647,000 | 42,206,000 | 38,506,000 | 40,408,000 | 36,925,000 | 31,998,000 | 30,069,000 | 29,943,000 | 26,708,000 | 20,053,000 | 20,434,000 | 19,419,000 | 17,206,000 | 14,143,000 | 13,161,000 | 14,799,000 | 18,356,000 | 15,243,000 | 22,007,000 | 18,578,000 | 16,755,000 | 15,235,000 |
other payables, lease liabilities and accrued expenses | 90,339,000 | 100,997,000 | 96,464,000 | 86,166,000 | 89,249,000 | 93,130,000 | 86,350,000 | 79,007,000 | 84,724,000 | 77,493,000 | 67,551,000 | 67,306,000 | 73,580,000 | 64,050,000 | 55,489,000 | 58,613,000 | 70,002,000 | 64,544,000 | 59,421,000 | 57,784,000 | 53,128,000 | 46,615,000 | 43,795,000 | 48,407,000 | 43,498,000 | 41,005,000 | ||||||||||||||||
total current liabilities | 217,578,000 | 223,228,000 | 776,006,000 | 749,634,000 | 743,305,000 | 756,376,000 | 735,002,000 | 169,178,000 | 179,115,000 | 157,161,000 | 150,087,000 | 148,775,000 | 158,777,000 | 141,076,000 | 135,399,000 | 127,799,000 | 142,602,000 | 124,549,000 | 116,206,000 | 110,487,000 | 113,612,000 | 95,334,000 | 85,121,000 | 84,203,000 | 86,311,000 | 80,405,000 | 73,567,000 | 70,948,000 | 64,560,000 | 48,087,000 | 45,247,000 | 44,759,000 | 50,202,000 | 40,985,000 | 35,171,000 | 31,915,000 | 36,882,000 | 29,712,000 | 34,618,000 | 29,428,000 | 28,627,000 | 25,915,000 |
long-term liabilities: | ||||||||||||||||||||||||||||||||||||||||||
senior secured credit facility | 195,461,000 | 195,047,000 | 194,639,000 | 97,609,000 | 97,450,000 | 97,300,000 | 97,149,000 | 96,962,000 | ||||||||||||||||||||||||||||||||||
long-term leases | 39,479,000 | 42,682,000 | 42,853,000 | 40,310,000 | 21,144,000 | 21,731,000 | 22,054,000 | 20,329,000 | 19,973,000 | 14,827,000 | 13,377,000 | 14,813,000 | 11,478,000 | 11,944,000 | 12,708,000 | 13,080,000 | 13,668,000 | 13,274,000 | 11,367,000 | |||||||||||||||||||||||
employee benefit liabilities | 4,691,000 | 3,938,000 | 6,515,000 | 6,320,000 | 5,768,000 | 6,940,000 | 7,892,000 | 6,023,000 | 8,258,000 | 5,373,000 | 4,840,000 | 5,143,000 | 4,404,000 | 4,088,000 | 3,598,000 | 3,024,000 | 4,543,000 | 5,171,000 | 3,754,000 | 3,610,000 | 2,823,000 | 2,683,000 | 2,347,000 | 2,473,000 | 2,522,000 | 2,453,000 | 2,489,000 | 2,679,000 | 2,756,000 | 2,590,000 | 3,132,000 | 2,592,000 | 2,823,000 | 2,057,000 | ||||||||
total long-term liabilities | 239,631,000 | 240,632,000 | 243,855,000 | 146,800,000 | 143,546,000 | 124,229,000 | 126,203,000 | 681,242,000 | 604,518,000 | 595,488,000 | 593,245,000 | 593,419,000 | 591,701,000 | 587,738,000 | 585,601,000 | 586,530,000 | 586,399,000 | 582,740,000 | 583,584,000 | 585,009,000 | 461,845,000 | 28,678,000 | 175,996,000 | 176,297,000 | 175,347,000 | 173,088,000 | 173,716,000 | 172,913,000 | 162,974,000 | 152,489,000 | 152,548,000 | 152,602,000 | 101,532,000 | 104,608,000 | 104,326,000 | 103,813,000 | 102,854,000 | 103,138,000 | 29,255,000 | 29,164,000 | 27,889,000 | 26,642,000 |
total liabilities | 457,209,000 | 463,860,000 | 1,019,861,000 | 896,434,000 | 886,851,000 | 880,605,000 | 861,205,000 | 850,420,000 | 783,633,000 | 752,649,000 | 743,332,000 | 742,194,000 | 750,478,000 | 728,814,000 | 721,000,000 | 714,329,000 | 729,001,000 | 707,289,000 | 699,790,000 | 695,496,000 | 575,457,000 | 124,012,000 | 261,117,000 | 260,500,000 | 261,658,000 | 253,493,000 | 247,283,000 | 243,861,000 | 227,534,000 | 200,576,000 | 197,795,000 | 197,361,000 | 151,734,000 | 145,593,000 | 139,497,000 | 135,728,000 | 139,736,000 | 132,850,000 | 63,873,000 | 58,592,000 | 56,516,000 | 52,557,000 |
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||
shareholders' equity: | ||||||||||||||||||||||||||||||||||||||||||
share capital - | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:115,820,940 shares and 112,492,667 shares at march 31, 2026 (unaudited) and december 31, 2025, respectively | ||||||||||||||||||||||||||||||||||||||||||
additional paid-in capital | 1,697,107,000 | 1,634,264,000 | 1,612,997,000 | 1,583,138,000 | 1,554,608,000 | 1,519,809,000 | 1,454,367,000 | 1,422,903,000 | 1,353,468,000 | 1,334,120,000 | 1,306,603,000 | 1,266,358,000 | 1,222,063,000 | 1,188,864,000 | 1,158,348,000 | 1,127,782,000 | 1,099,589,000 | 1,073,532,000 | 1,044,732,000 | 1,005,785,000 | 1,111,435,000 | 946,267,000 | 916,632,000 | 892,510,000 | 871,442,000 | 848,151,000 | 818,338,000 | 783,941,000 | 757,314,000 | 744,087,000 | 729,684,000 | 708,266,000 | 697,165,000 | 689,460,000 | 679,099,000 | 669,462,000 | 664,154,000 | 658,086,000 | 652,460,000 | 645,919,000 | 640,406,000 | 476,377,000 |
accumulated other comprehensive income | -4,895,000 | -3,441,000 | -5,806,000 | -5,109,000 | -4,201,000 | -5,500,000 | -5,378,000 | -3,515,000 | -5,469,000 | -1,992,000 | -1,981,000 | -2,691,000 | -2,433,000 | -2,306,000 | -2,095,000 | -1,328,000 | -3,169,000 | -900,000 | -1,119,000 | -1,948,000 | -3,236,000 | -3,532,000 | -3,629,000 | -2,641,000 | -2,357,000 | -1,742,000 | -1,127,000 | |||||||||||||||
retained earnings | -1,361,495,000 | -1,290,357,000 | -1,265,858,000 | -1,228,588,000 | -1,188,449,000 | -1,154,130,000 | -1,088,208,000 | -1,057,638,000 | -985,503,000 | -938,424,000 | -888,939,000 | -831,521,000 | -778,460,000 | -741,157,000 | -714,581,000 | -690,573,000 | -685,926,000 | -659,468,000 | -646,344,000 | -631,703,000 | -635,994,000 | -645,278,000 | -646,933,000 | -655,145,000 | -657,075,000 | -655,805,000 | -628,024,000 | |||||||||||||||
total shareholders' equity | 330,717,000 | 341,333,000 | 349,441,000 | 361,958,000 | 360,781,000 | 361,750,000 | 393,704,000 | 415,683,000 | 432,146,000 | 445,401,000 | 441,672,000 | 435,881,000 | 413,164,000 | 397,269,000 | 372,134,000 | 307,037,000 | 267,822,000 | 241,948,000 | 190,365,000 | 158,906,000 | 126,394,000 | 114,936,000 | 112,081,000 | 106,118,000 | 116,685,000 | 117,545,000 | 128,900,000 | 158,243,000 | 186,646,000 | 220,426,000 | 121,224,000 | |||||||||||
total liabilities and shareholders' equity | 787,926,000 | 1,361,194,000 | 1,245,875,000 | 1,248,809,000 | 1,221,986,000 | 1,212,170,000 | 1,146,353,000 | 1,159,015,000 | 1,174,340,000 | 1,174,215,000 | 1,162,672,000 | 1,150,210,000 | 1,120,453,000 | 1,097,059,000 | 1,067,630,000 | 431,049,000 | 528,939,000 | 502,448,000 | 443,858,000 | 406,189,000 | 370,255,000 | 315,512,000 | 309,876,000 | 303,479,000 | 262,278,000 | 257,042,000 | 264,628,000 | 291,093,000 | 250,519,000 | 279,018,000 | 173,781,000 | |||||||||||
u.s. dollars in thousands, except share and per share data | 2,025,000 | 2,024,000 | 2,023,000 | 2,022,000 | 2,021,000 | 2,020,000 | 2,019,000 | 2,018,000 | 2,017,000 | 2,016,000 | 2,015,000 | |||||||||||||||||||||||||||||||
liabilities and shareholders’ equity | ||||||||||||||||||||||||||||||||||||||||||
convertible note | 560,620,000 | 559,790,000 | 558,970,000 | 558,160,000 | 557,333,000 | 556,508,000 | ||||||||||||||||||||||||||||||||||||
long term leases | 41,647,000 | 19,971,000 | 27,420,000 | 18,762,000 | 12,997,000 | 14,293,000 | 14,140,000 | |||||||||||||||||||||||||||||||||||
shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 112,492,667 shares and 108,516,819 shares at december 31, 2025 and december 31, 2024 respectively; | ||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity | 340,466,000 | 360,179,000 | 362,496,000 | 441,170,000 | 410,494,000 | 476,526,000 | 217,790,000 | 112,259,000 | 113,564,000 | 142,345,000 | 250,820,000 | |||||||||||||||||||||||||||||||
total liabilities and shareholders’ equity | 804,326,000 | 1,240,784,000 | 1,146,129,000 | 1,191,648,000 | 1,139,495,000 | 1,051,983,000 | 479,448,000 | 339,793,000 | 265,298,000 | 282,081,000 | 307,336,000 | |||||||||||||||||||||||||||||||
other long-term liabilities | 19,000 | 18,000 | 18,000 | 18,000 | 18,000 | 18,000 | 18,000 | 75,000 | 119,000 | 136,000 | 148,000 | 222,000 | 239,000 | 156,000 | 166,000 | 379,000 | 173,000 | 177,000 | 337,000 | 168,000 | 173,000 | 267,000 | 222,000 | 295,000 | 306,000 | 363,000 | 1,094,000 | 911,000 | 880,000 | 920,000 | 1,737,000 | 5,070,000 | 4,882,000 | 4,565,000 | 4,033,000 | 4,036,000 | 3,371,000 | 3,148,000 | 2,735,000 | 1,840,000 | ||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:111,979,981 shares and 108,516,819 shares at september 30, 2025 (unaudited) and december 31, 2024, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:111,798,690 shares and 108,516,819 shares at june 30, 2025 (unaudited) and december 31, 2024, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:111,482,600 shares and 108,516,819 shares at march 31, 2025 (unaudited) and december 31, 2024, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 108,516,819 shares and 107,075,754 shares at december 31, 2024 and december 31, 2023 respectively; | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:108,100,392 shares and 107,075,754 shares at september 30, 2024 (unaudited) and december 31, 2023, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:108,013,830 shares and 107,075,754 shares at june 30, 2024 (unaudited) and december 31, 2023, respectively | ||||||||||||||||||||||||||||||||||||||||||
long-term debt | 568,822,000 | 567,986,000 | 567,150,000 | 566,324,000 | 565,509,000 | 564,677,000 | 563,846,000 | 563,026,000 | 562,216,000 | 561,388,000 | 560,562,000 | 559,584,000 | 429,905,000 | |||||||||||||||||||||||||||||
deferred revenues | 807,000 | 1,843,000 | 2,878,000 | 6,477,000 | 12,139,000 | 7,807,000 | 9,929,000 | |||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 107,075,754 shares and 105,049,411 shares at december 31, 2023 and december 31, 2022 respectively; | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:106,748,270 shares and 105,049,411 shares at september 30, 2023 (unaudited) and december 31, 2022, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:106,605,331 shares and 105,049,411 shares at june 30, 2023 (unaudited) and december 31, 2022, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:106,187,162 shares and 105,049,411 shares at march 31, 2023 (unaudited) and december 31, 2022, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 105,049,411 shares and 103,971,263 shares at december 31, 2022 and december 31, 2021 respectively; | ||||||||||||||||||||||||||||||||||||||||||
deferred revenue | 3,924,000 | 4,541,000 | 5,511,000 | 7,464,000 | 8,352,000 | 9,577,000 | 10,859,000 | 8,022,000 | 8,772,000 | 8,341,000 | 8,874,000 | 9,407,000 | ||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:104,942,941 shares and 103,971,263 shares at september 30, 2022 (unaudited) and december 31, 2021, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:104,727,685 shares and 103,971,263 shares at june 30, 2022 (unaudited) and december 31, 2021, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:104,559,088 shares and 103,971,263 shares at march 31, 2022 (unaudited) and december 31, 2021, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 103,971,263 shares and 102,334,276 shares at december 31, 2021 and december 31, 2020 respectively; | ||||||||||||||||||||||||||||||||||||||||||
employee benefits | 2,031,000 | 2,553,000 | 2,963,000 | 4,571,000 | 4,626,000 | 4,519,000 | 3,701,000 | |||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:103,817,566 shares and 102,334,276 shares at september 30, 2021 (unaudited) and december 31, 2020, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:103,641,238 shares and 102,334,276 shares at june 30, 2021 (unaudited) and december 31, 2020, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:103,187,460 shares and 102,334,276 shares at march 31, 2021 (unaudited) and december 31, 2020, respectively | ||||||||||||||||||||||||||||||||||||||||||
other payables and accrued expenses | 59,965,000 | 49,386,000 | 37,852,000 | 28,034,000 | 24,813,000 | 25,340,000 | 32,996,000 | 26,842,000 | 22,010,000 | 17,116,000 | 18,526,000 | 14,469,000 | 12,611,000 | 10,850,000 | 11,872,000 | 10,680,000 | ||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 102,334,276 shares and 99,528,435 shares at december 31, 2020 and december 31, 2019 respectively; | ||||||||||||||||||||||||||||||||||||||||||
accumulated other comprehensive loss | -3,832,000 | -2,767,000 | -1,400,000 | -1,273,000 | -1,328,000 | -1,343,000 | -1,462,000 | -1,739,000 | -1,921,000 | -1,883,000 | -2,085,000 | -1,684,000 | -1,975,000 | -1,505,000 | ||||||||||||||||||||||||||||
accumulated deficit | -631,077,000 | -650,885,000 | -643,655,000 | -616,330,000 | -600,820,000 | -582,258,000 | -571,313,000 | -559,815,000 | -538,641,000 | -519,926,000 | -497,758,000 | -464,130,000 | -423,518,000 | -388,081,000 | -355,153,000 | |||||||||||||||||||||||||||
long-term loan, net of discount and issuance costs | 149,507,000 | 149,465,000 | 149,424,000 | 149,384,000 | 149,344,000 | 149,305,000 | 149,268,000 | 149,231,000 | 149,195,000 | 149,160,000 | 97,342,000 | 97,049,000 | 96,765,000 | 96,492,000 | 96,231,000 | 95,970,000 | 23,292,000 | 23,193,000 | 23,097,000 | |||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:101,728,327 shares and 99,528,435 shares at september 30, 2020 (unaudited) and december 31, 2019, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:101,020,721 shares and 99,528,435 shares at june 30, 2020 (unaudited) and december 31, 2019, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:100,362,973 shares and 99,528,435 shares at march 31, 2020 (unaudited) and december 31, 2019, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 99,528,435 shares and 93,254,185 shares at december 31, 2019 and december 31, 2018 respectively; | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding:98,948,935 shares and 93,254,185 shares at september 30, 2019 (unaudited) and december 31, 2018, respectively | ||||||||||||||||||||||||||||||||||||||||||
long-term lease liabilities | 11,582,000 | 11,015,000 | ||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 97,858,876 shares and 93,254,185 shares at june 30, 2019 (unaudited) and december 31, 2018, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 95,692,797 shares and 93,254,185 shares at march 31, 2019 (unaudited) and december 31, 2018, respectively | ||||||||||||||||||||||||||||||||||||||||||
severance pay fund | 113,000 | 114,000 | 111,000 | 113,000 | 111,000 | 104,000 | 102,000 | 95,000 | 88,000 | 89,000 | 82,000 | 84,000 | 79,000 | 75,000 | ||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 93,254,185 shares and 89,478,032 shares at december 31, 2018 and december 31, 2017 respectively; | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 93,007,844 shares and 89,478,032 shares at september 30, 2018 (unaudited) and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 92,503,273 shares and 89,478,032 shares at june 30, 2018 (unaudited) and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 90,398,901 shares and 89,478,032 shares at march 31, 2018 (unaudited) and december 31, 2017, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 89,478,032 shares and 87,066,446 shares at december 31, 2017 and december 31, 2016 respectively; | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 89,355,679 shares and 87,066,446 shares at september 30, 2017 (unaudited) and december 31, 2016, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 88,630,205 shares and 87,066,446 shares at june 30, 2017 (unaudited) and december 31, 2016, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 88,133,366 shares and 87,066,446 shares at march 31, 2017 (unaudited) and december 31, 2016, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 87,066,446 shares and 83,778,581 shares at december 31, 2016 and december 31, 2015 respectively; | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,775,203 (unaudited) shares and 83,778,581 shares at september 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized; issued and outstanding: 85,774,774 shares and 83,778,581 shares at june 30, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares no par value, unlimited shares authorized ; issued and outstanding: 84,426,720 shares and 83,778,581 shares at march 31, 2016 and december 31, 2015, respectively | ||||||||||||||||||||||||||||||||||||||||||
ordinary shares - no par value, unlimited shares authorized; issued and outstanding: 83,778,581 shares and 13,431,414 shares at december 31, 2015 and december 31, 2014 respectively; | ||||||||||||||||||||||||||||||||||||||||||
preferred shares - no par value, unlimited shares authorized; issued and outstanding: zero shares and 58,676,017 shares at december 31, 2015 and december 31, 2014 respectively; | ||||||||||||||||||||||||||||||||||||||||||
deferred ipo costs | 2,577,000 | |||||||||||||||||||||||||||||||||||||||||
long-term loan, net of discount | 24,554,000 | |||||||||||||||||||||||||||||||||||||||||
accrued severance pay | 248,000 | |||||||||||||||||||||||||||||||||||||||||
ordinary shares—unlimited no par value shares authorized; issued and outstanding: 12,432,293 shares and 13,431,414 shares at september 30, 2015 (unaudited), and december 31, 2014, respectively; | ||||||||||||||||||||||||||||||||||||||||||
preferred shares—unlimited no par value shares authorized; issued and outstanding: 62,744,517 shares and 58,676,017 shares at september 30, 2015 (unaudited), and december 31, 2014, respectively; |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2015-12-31 |
|---|---|
cash flows from operating activities: | |
net income | |
adjustments to reconcile net income to net cash from operating activities: | |
depreciation and amortization | |
accrued interest | |
asset write-downs and impairment of field equipment | |
share-based compensation | |
foreign currency remeasurement loss | |
decrease in accounts receivables and prepaid expenses | |
amortization of discount | 98,000 |
decrease in inventories | |
decrease in other long-term assets | |
increase in accounts payables and accrued expenses | |
increase in other long-term liabilities | 904,000 |
net cash from operating activities | -26,121,000 |
capital expenditures | -1,054,000 |
free cash flows | -27,175,000 |
cash flows from investing activities: | |
purchase of property, equipment and field equipment | |
proceeds from maturity of short-term investments | 27,000,000 |
purchase of short-term investments | -150,006,000 |
net cash from investing activities | -126,038,000 |
cash flows from financing activities: | |
proceeds from issuance of shares | |
proceeds from senior secured credit facility | |
repayment and redemption of long-term debt | |
tax payments related to net settlements on equity awards | |
exercise of options | |
net cash from financing activities | 161,258,000 |
effect of exchange rate changes on cash, cash equivalents and restricted cash | |
increase in cash, cash equivalents and restricted cash | |
cash, cash equivalents and restricted cash at the beginning of the period | |
cash, cash equivalents and restricted cash at the end of the period | |
supplemental cash flow activities: | |
cash paid during the period for: | |
income taxes paid (refunded) | |
interest paid | |
u.s. dollars in thousands | |
cash, cash equivalents and restricted cash at the beginning of the year | |
cash, cash equivalents and restricted cash at the end of the year | |
cash paid during the year for: | |
reconciliation of cash, cash equivalents and restricted cash: | |
cash and cash equivalents | |
restricted cash | |
total cash, cash equivalents and restricted cash | |
non-cash activities: | |
right-of-use assets obtained in exchange for lease liabilities | |
purchase of property incurred but unpaid at period end | |
foreign currency remeasurement gain | |
decrease (increase) in accounts receivables and prepaid expenses | |
decrease (increase) in inventories | |
decrease (increase) in other long-term assets | |
repayment of long-term debt | |
decrease in accounts receivables | |
proceeds from convertible note | |
proceeds from long term debt | |
repayment of long-term loan | |
exercise of options and warrants | 2,007,000 |
proceeds from long-term debt | |
interest | 5,000 |
income taxes, net of refunds | |
non-cash activities in accordance with asc-842: | |
right-of-use assets obtained in exchange for lease obligations | |
income taxes | 666,000 |
adjustments to reconcile net loss to net cash from operating activities: | |
proceeds from long-term loan | |
share-based compensation to employees | 4,488,000 |
effect of foreign currency translation | |
decrease in trade receivables | |
decrease in receivables and prepaid expenses | |
decrease in right of use assets | |
increase in trade payables | 2,364,000 |
increase in other payables and accrued expenses | 687,000 |
increase in employee benefit liabilities | |
increase in long-term lease liability | |
purchase of property and equipment | -1,054,000 |
purchase of field equipment | -2,057,000 |
repayment of other long-term loan | |
effect of exchange rate changes on cash and cash equivalents | |
cash, cash equivalents and restricted cash at beginning of period | |
non-cash activities upon implementation of asc-842: | |
right of use assets obtained in exchange for lease obligations | |
right of use assets obtained in exchange for lease obligations: | |
excess tax benefits from share-based award activity | |
proceeds from issuance of other long-term loans | |
repayment of other long-term loans | |
proceeds from other long-term loans | |
net loss | |
increase in trade receivables | |
increase in other long-term assets | |
adjustments to reconcile net loss to net cash from (used in) operating activities: | |
increase in accrued interest expense | |
increase in restricted cash | |
purchase of shares in respect of settlement | |
increase in cash and cash equivalents | 9,099,000 |
cash and cash equivalents at the beginning of the year | |
cash and cash equivalents at the end of the year | |
decrease in restricted cash | |
cash and cash equivalents at the beginning of the period | |
cash and cash equivalents at the end of the period | |
decrease in cash and cash equivalents | |
increase in inventories | |
non-cash investing and financing activities: | |
other comprehensive loss, net of tax : | |
change in foreign currency translation adjustments | |
pension benefit plan | |
total comprehensive loss | |
balance as of january 1, 2015 | |
issuance of series j preferred shares | |
issuance of shares and options in respect of settlement, net of fair value of shares provided as indemnification | |
issuance of ordinary shares upon ipo and exercise of over-allotment | |
conversion of preferred shares to ordinary shares | |
other comprehensive loss, net of tax benefit | |
balance as of december 31, 2015 | |
balance as of september 30, 2016 | |
deferred ipo costs | |
balance as of june 30, 2016 | |
accrued interest expense | 518,000 |
increase in receivables and prepaid expenses | -635,000 |
balance as of march 31, 2016 | |
asset write-downs and impairment | 4,000 |
non-cash investing activity: | |
long-term loan issuance costs and discount | |
repayment of long-term loans | |
depreciation | |
increase in severance pay | |
decrease (increase) in restricted cash | |
proceeds from issuance of preferred shares | |
proceeds from issuance of long-term loan | |
purchase of shares | |
supplemental cash flow data | |
non-cash financing activities: |